← Back to patent-cliff list
Atidafonat tosylate
Tier C — Watch / tradeAtidafonat tosylate
Chugai Pharmaceutical Co., Ltd.
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：NaPi-2b, SLC20A1, SLC20A2
Indications (approved)：Hyperphosphataemia, Chronic renal impairment, End-stage renal disease, Nephropathy
Regional status
US
Phase II
2026-06-01
EU
-
China
Phase II
2023-02-20
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Atidafonat tosylate?
Approved indications include: Hyperphosphataemia, Chronic renal impairment, End-stage renal disease, Nephropathy.
When does the Atidafonat tosylate patent expire?
No public expiry year is available for Atidafonat tosylate yet; this page updates once verified.
How do I get a quote for Atidafonat tosylate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-03